Novel therapies in metastatic head and neck squamous cell carcinoma

Community Oncology

Volumn 6, Issue 7, 2009, Pages 310-316

  Tsao, Anne S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; LAPATINIB; LONAFARNIB; ONYX 015; PACLITAXEL; PELITINIB; PEMETREXED; PLACEBO; PLATINUM; SUNITINIB; TIPIFARNIB;

ADD ON THERAPY; AIRWAY OBSTRUCTION; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPHAGIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INJECTION SITE REACTION; LUNG HEMORRHAGE; LYMPHOCYTOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGNOSIS; PROTEINURIA; RASH; REVIEW; SEPSIS; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TRACHEOESOPHAGEAL FISTULA; TREATMENT DURATION; TREATMENT FAILURE; TUMOR BLEEDING; VOMITING;

EID: 68049112418     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70246-7     Document Type: Review

References (43)

1. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamouscell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
2. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
3. Glisson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593-1599. (Pubitemid 34260540)
4. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/ carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group phase II study. Cancer Invest 2007;25:182-188. (Pubitemid 47164860)
5. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. (Pubitemid 43209104)
6. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654. (Pubitemid 46211507)
7. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 2007;25:2178-2183. (Pubitemid 46954640)
8. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
9. Kim E, Tsao A, William W, et al. A phase II study of erlotinib in combination with cisplatin and docetaxel in metastatic or recurrent head and neck squamous cell carcinoma. J Clin Oncol 2007;25(18S):6013.
10. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-2177.
11. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85. (Pubitemid 41095117)
12. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587. (Pubitemid 46300152)
13. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum- based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577. (Pubitemid 46300151)
14. Vermorken JB, Herbst RS, Leon X, et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008;112:2710-2719.
15. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987. (Pubitemid 46606387)
16. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-8424.
17. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
19. Kies M, Gibson M, Kim S, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): an interim analysis. J Clin Oncol 2008;26(15S):6072.
20. Feinstein T, Raez L, Rajasenan K, et al. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial. J Clin Oncol 2008;26(15S):6069.
21. Choong N, Cohen E, Kozloff M, et al. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008;26(15S):6064.
22. Machiels J, Henry S, Zanetta S, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic squamous head and neck carcinoma GORTEC 2006-01. J Clin Oncol 2009;27(15S):6024.
23. Saura C, Baselga J, Herbst RS, et al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer or recurrent NSCLC: an open label exploratory study. J Clin Oncol 2009;27(15S): 6023.
24. Hainsworth J, Herbst RS. A phase III, multicenter, placebo-controlled, double-blind randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced NSCLC after failure of standard frontline chemotherapy (BETA). J Thorac Oncol 2008;3(suppl 4):S302.
25. Ciuleanu T, Brodowicz T, Belani C, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008;26(15S):8011.
26. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
27. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596. (Pubitemid 44546920)
28. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002;14:334-342. (Pubitemid 34492868)
29. Yang C, Kies M, Glisson B, et al. A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2005;23(16S):5565.
30. Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102:1674-1681. (Pubitemid 28516252)
31. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000;9:2903-2911.
32. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806. (Pubitemid 30159332)
33. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-298. (Pubitemid 32112839)
34. Vattemi E, Claudio PP. Adenoviral gene therapy in head and neck cancer. Drug News Perspect 2006;19:329-337. (Pubitemid 44409884)
35. Chen Z, Zhang X, Li M, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:5930-5939. (Pubitemid 39180975)
36. Lippman SM, Gibson N, Subbaramaiah K, et al. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005;11:6097-6099. (Pubitemid 41262933)
37. Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:6976-6981. (Pubitemid 46260283)
38. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-959. (Pubitemid 46452288)
39. Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and nonsmall cell lung cancer cells. Clin Cancer Res 2005;11:6924-6932.
40. Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008;20:256-263.
41. Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-4299.
42. Karp D, Paz-Ares L, Novello S, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008;26(15S):8015.
43. Lcitra L, Rolland F, Bokemeyer C, et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT plus cetuximab in first-line recurrent/metastatic SCCHN. J Clin Oncol 2009;27(15S):6005.